Radar Telegram alerts Open Radar

BioNTech and DualityBio announce topline results of the DYNASTY-Breast02 Global Phase 3 clinical trial evaluating Trastuzumab Pamirtecan in HR+ / HER2-low metastatic breast cancer.

Business Insider Markets · Source

BioNTech and DualityBio announce topline results of the DYNASTY-Breast02 Global Phase 3 clinical trial evaluating Trastuzumab Pamirtecan in HR+ / HER2-low metastatic breast cancer.